

List of Figures

Figures	Title	Page
1.1	Overview of structure, functions and regulations of autocrine motility factor receptor (AMFR)/Glycoprotein 78 (Gp78)	8
2.1	Gp78, as a vital E3 ubiquitin ligase of endoplasmic reticulum-associated degradation	11
2.2	Functional implications of Gp78 in cancer	15
2.3	Targeting AMFR/Gp78 for remedial exploration of various maladies	17
3.1	Expression profile of Gp78	24
3.2	Comparison of exogenous and endogenous expression of Gp78	24
3.3	Gp78 overexpression increases the endogenous levels of p27	25
3.4	E6-AP as ligase control for p27	26
3.5	Effect of Gp78 mutation on p27 accumulation	27
3.6	p27 is degraded by proteasome	28
3.7	Upregulation of p27 following Gp78 overexpression	29
3.8	Observation of effect of lower doses of Gp78 on p27	30
3.9	Change in p27 RNA by Gp78 overexpression	30
3.10	Accumulation of p27-positive inclusions in Gp78 overexpressed cells	31
3.11	Control immunocytochemistry for p27 antibodies	32
3.12	Immunocytochemistry of p53 in Gp78 overexpressed cell	32
3.13	Immunocytochemistry of p21 in Gp78 overexpressed cells	33
3.14	Gp78 overexpression stabilizes p27 in cells	34
3.15	Expression analysis of P-p27 in Gp78 overexpressed cells	35
3.16	Immunoblot analysis of P-p27 in cells	35
3.17	Gp78 depletion affects cellular proliferation	36
3.18	Effect of Gp78 overexpression on cell proliferation	37
3.19	Effect of p27-siRNA on cell proliferation	38
3.20	Effect of Gp78 overexpression on the levels of CDK4	38
3.21	Analysis of cyclin D1 in Gp78 overexpressed cells	39
3.22	Analysis of cyclin E level in Gp78 overexpressed cells	39
3.23	Immunoblot analysis of various cell cycle regulatory proteins	40
3.24	Immunocytochemistry analysis of Gp78 siRNA	40
3.25	Effect of Gp78 siRNA on p27	41
3.26	RT-PCR analysis of Gp78 siRNA	41
3.27	Immunoblot analysis of Gp78 siRNA transfection	42
3.28	Effect of tunicamycin treatment on cells	43
3.29	PCR analysis after tunicamycin concentration dependent treatment	43
3.30	Expression analysis of Gp78 and p27 after tunicamycin treatment	44
4.1	Myricetin affects endogenous levels of QC E3 ubiquitin ligase E6-AP, and chaperone Hsp70	48
4.2	Affect on HSF1 by Myricetin treatment	48
4.3	Effect of Myricetin concentration dependent treatment	49
4.4	Effect of Myricetin time dependent treatment	49
4.5	Observation of Myricetin treatment to GFP-wtCAT transfected cells	50
4.6	Myricetin treatment to GFP-wtCAT transfected cells with MG132	50
4.7	Effect of Myricetin treatment on mutant GFP-Δ9CAT inclusions	51
4.8	Effect of Myricetin on inclusion formation following proteasome inhibition	51
4.9	Analysis of E6-AP and luciferase co-localization	52
4.10	Monitoring the co-localization of luciferase and Hsp70	53
4.11	Luciferase activity assay and immunoblot analysis	53
4.12	Myricetin provide cytoprotection from various stresses	54
4.13	Myricetin-mediated ubiquitination of GFP-SOD1-WT	55
4.14	Myricetin-mediated ubiquitination of GFP-SOD1-WT in presence of MG132	55
4.15	Myricetin-mediated ubiquitin localization with GFP-SOD1-G37R aggregates	56
4.16	Myricetin-mediated localization of ubiquitin with GFP-SOD1-G37R in presence of MG132	56
4.17	Effect of Myricetin on accumulation of α-Synuclein protein	57
4.18	Effect of MG132 on Myricetin-mediated ubiquitination of α-Synuclein	57
4.19	Myricetin-mediated suppression of aggregation propensity of α-Synuclein mutant S87A	58

	<i>aggregates</i>	
4.20	<i>Effect of proteasomal inhibition on Myricetin mediated aggregate clearance</i>	58
4.21	<i>In-silico analysis of Myricetin interaction with E6-AP</i>	59
4.22	<i>Myricetin stabilizes E6-AP in cells</i>	60
4.23	<i>Myricetin treatment to cells expressing EGFP-HD23Q</i>	61
4.24	<i>Monitoring the effect of MG132 treatment on Myricetin treated EGFP-HD23Q expressing cells</i>	61
4.25	<i>Myricetin reduces aggregates of EGFP-HD-74Q</i>	62
4.26	<i>Myricetin reduces aggregates of EGFP-HD-74Q in presence of MG132</i>	62
4.27	<i>Myricetin treatment suppressed the aggregation of neurodegenerative diseases associated abnormal proteins</i>	63
4.28	<i>Myricetin treatment suppressed the aggregation of EGFP-Ataxin-3(84Q) proteins</i>	63
4.29	<i>Myricetin treatment suppresses the expanded polyglutamin proteins</i>	64
4.30	<i>Myricetin treatment reduces the aggregation of neurodegenerative diseases associated abnormal proteins</i>	65
5.1	<i>Model proposed for Gp78 mediated cell cycle regulation.</i>	69